{"id":"gsk5764227","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TYK2 is a non-receptor tyrosine kinase that plays a critical role in signal transduction downstream of type I and type III interferons and IL-23 signaling. By selectively inhibiting TYK2, GSK5764227 reduces the activation and differentiation of pro-inflammatory immune cells, particularly Th17 cells, thereby dampening pathogenic immune responses in autoimmune and inflammatory conditions.","oneSentence":"GSK5764227 is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses inflammatory signaling pathways involved in immune-mediated diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:44.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT05277051","phase":"PHASE1","title":"First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-03-22","conditions":"Neoplasms","enrollment":152},{"nctId":"NCT07464327","phase":"PHASE3","title":"A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2026-03-31","conditions":"Non-Small Cell Lung Cancer","enrollment":450},{"nctId":"NCT07099898","phase":"PHASE3","title":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-11","conditions":"Neoplasms, Lung","enrollment":420},{"nctId":"NCT07268053","phase":"EARLY_PHASE1","title":"A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases","status":"RECRUITING","sponsor":"Nader Sanai","startDate":"2026-02-11","conditions":"Glioblastoma (GBM), Brain Metastasases","enrollment":15},{"nctId":"NCT07408063","phase":"PHASE2","title":"A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-02-02","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT07277270","phase":"PHASE1","title":"A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-12-03","conditions":"Neoplasms","enrollment":84},{"nctId":"NCT06551142","phase":"PHASE1","title":"A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-30","conditions":"Neoplasms","enrollment":590},{"nctId":"NCT06885034","phase":"PHASE1, PHASE2","title":"A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-06-11","conditions":"Gastrointestinal Neoplasms","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK5764227","genericName":"GSK5764227","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK5764227 is being studied in a first-time-in-human clinical trial for advanced solid tumors, including conditions such as glioblastoma, brain metastases, and gastrointestinal neoplasms. The study is evaluating the safety and efficacy of GSK5764227, although specific details about its mechanism of action are not provided in the available information.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}